The market for psychedelic drugs to treat mental health conditions gets a big buy signal
Eli Lilly's acquisition of psychedelic drug maker AtaiBeckley extends Big Pharma's embrace of a stigmatized class of medications for treating mental health.
By · July 19, 2026 · 1 min read
This article was originally published by
CNBC Top News
and is republished here under license.
Eli Lilly’s acquisition of psychedelic drug maker AtaiBeckley extends Big Pharma’s embrace of a stigmatized class of medications for treating mental health.
Leave a Reply